No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATHA240816C5000
- 0.22
- -0.33-60.00%
15min DelayClose Jul 19 16:00 ET
0.22High0.22Low
0.22Open0.55Pre Close5 Volume7 Open Interest5.00Strike Price110.00Turnover203.11%IV67.85%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type0.2737Delta0.1981Gamma14.14Leverage Ratio-0.0109Theta0.0004Rho3.87Eff Leverage0.0028Vega
Intraday
- 5D
- Daily
News
Mizuho Securities Maintains Athira(ATHA.US) With Buy Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Athira(ATHA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of -3.9% over
Mizuho Securities Keeps Their Buy Rating on Athira Pharma (ATHA)
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Sector Update: Health Care
Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) adding 0.4%.The iShares Biotechnology ETF (
Athira Pharma Doses Last Patient Alzheimer's Treatment Study
Athira Pharma (ATHA) said Tuesday it has dosed the last patient in the phase 2/3 for fosgonimeton in patients with mild-to-moderate Alzheimer's disease.The company aims to release top-line results
Express News | Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Comments
1
$Athira(ATHA.US$
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
$Athira(ATHA.US$ Benzinga· 5 mins ago
Athira Pharma To Be Issued US Patent For "Methods Of Treating Parkinson's Disease And Lewy Body Disease
Athira Pharma To Be Issued US Patent For "Methods Of Treating Parkinson's Disease And Lewy Body Disease
$Athira(ATHA.US$
NEWS
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma, Inc. announces promising preclinical data on fosgonimeton for Alzheimer's disease treatment. Fosgonimeton shows neuroprotective effects, counteracts Aβ-induced toxicity, and enhances neuronal health. Key findings include improved neuronal survival, reduced tau hyperphosphorylation, enhanced activation of pro-survival effectors, and cog...
NEWS
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma, Inc. announces promising preclinical data on fosgonimeton for Alzheimer's disease treatment. Fosgonimeton shows neuroprotective effects, counteracts Aβ-induced toxicity, and enhances neuronal health. Key findings include improved neuronal survival, reduced tau hyperphosphorylation, enhanced activation of pro-survival effectors, and cog...
$Athira(ATHA.US$ Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference
Benzinga· 2 mins ago
Benzinga· 2 mins ago
1
Read more